Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer (NCT07408999) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer
France327 participantsStarted 2026-03-31
Plain-language summary
Esophageal and gastroesophageal junction cancers remain associated with poor survival despite progress in multimodal treatment. Surgery, especially Ivor-Lewis esophagectomy, combined with peri-operative therapy improves survival but is burdened by major morbidity, mainly respiratory and anastomotic complications, which compromise recovery and adjuvant treatment.
Minimally invasive approaches such as totally minimally invasive esophagectomy (TMIE) have shown potential to reduce postoperative morbidity compared to the hybrid approach (HE). However, existing studies are heterogeneous, mostly retrospective, and insufficient to establish a standard.
This trial aims to provide high-level evidence comparing TMIE to HE, including robotic techniques, with integrated analyses of clinical outcomes, quality of life, and health economics.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Inclusion criteria for screening - part A (for patients receiving a neo-adjuvant treatment)
* Age ≥ 18 years and ≤ 80 years For patients between 70 and 80 years old : score G8 ≥ 14 or oncogeratrician approval
* Squamous cell carcinoma or adenocarcinoma of the esophagus or esogastric junction
* Clinical stage T1, T2, T3, T4a, N0-N3, M0 before any treatment
* Tumors of the middle or lower third of the esophagus, or tumor of the esogastric junction Siewert 1 or 2
* With or without neoadjuvant (radio) chemotherapy ± targeted therapy
* Disease deemed curatively resectable preoperatively
* Requiring a 2-stage Ivor-Lewis esophagectomy
* Performance status 0, 1 or 2
* Patient capable of receiving either surgical treatment
* Patient informed of the terms of the study and having given written consent
* Patient able to read and understand the language and content of the study documents and agreeing to adhere to the protocol requirements.
* Covered by a medical/health insurance
* Willingness and ability to comply with scheduled visits and study procedures
Inclusion criteria before surgery (after neo-adjuvant treatment or for patients receiving primary surgery)
* Age ≥ 18 years and ≤ 80 years For patients between 70 and 80 years old : score G8 ≥ 14 or oncogeratrician approval
* Squamous cell carcinoma or adenocarcinoma of the esophagus or esogastric junction
* Clinical stage T1, T2, T3, N0-N3, M0 before surgery
* Tumors of the middle or lower third of the esophagus…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.